Government welcomes the approval of AstraZeneca/Oxford vaccine
-
The formula developed by AstraZeneca together with the University of Oxford requires two doses administered 28 days apart from each other.
-
Currently the vaccine is under clinical studies lead by the Universidad de Chile Clinical Hospital and the Luis Calvo Mackenna Hospital.
Public Health Undersecretary Paula Daza rated as “very good news” the information that the Advisory Council of the Public Health Institute unanimously approved the emergency use of the AstraZeneca/Oxford vaccine for people over 18 years of age.
“We know that this is a safe and effective vaccine, and it will allow us to continue with the vaccination calendar in our country,” she affirmed.
The formula developed by AstraZeneca together with the University of Oxford requires two doses administered 28 days apart from each other. Currently the vaccine is under clinical studies in Chile, led by the Universidad de Chile Clinical Hospital and the Luis Calvo Mackenna Hospital.
Acting Science Minister Carolina Torrealba emphasized that “less than a year after the pandemic was declared, the world of science has managed to find concrete answers to confront this crisis through research, innovation and the creation of new technologies that today are focused on vaccines that have been proven safe for the world population.”
International Economic Relations Undersecretary Rodrigo Yáñez explained that this is the third vaccine approved by the Chilean Public Health Institute and it will “allow us to define the strategy. This goes hand in hand with the contracts that the government has been negotiating with AstraZeneca Laboratory and the COVAX mechanism that is going to allow us to acquire 6,650,000 doses in March and April, within the first quarter of 2021 in order to reach our goal of 15 million vaccines to immunize the majority of the target population.”